{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-022910","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.692719+00:00","generated_at":"2026-06-22T03:55:57.343310+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fulcrum Therapeutics Q3 net loss $23.7M; cash $221.8M; selected 12mg dose for FTX-6058 SCD trial","bullets":["Net loss $23.7M vs $20.7M year ago; collaboration revenue fell to $1.2M from $4.9M due to Acceleron wind-down.","Cash, equivalents, and marketable securities $221.8M; cash runway guidance extended into late 2024.","Completed equity raise of ~$80.8M net proceeds in August 2022.","Selected 12mg as dose for next FTX-6058 Phase 1b cohort in sickle cell disease; enrollment continues.","Appointed Santiago Arroyo as CMO and Jeff Jacobs as CSO; losmapimod Phase 3 REACH trial enrollment ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-022910","json":"https://secwatch.observer/filing/0000950170-22-022910.json","markdown":"https://secwatch.observer/filing/0000950170-22-022910.md","text":"https://secwatch.observer/filing/0000950170-22-022910.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000095017022022910/0000950170-22-022910-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000095017022022910/fulc-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:55:57.343310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b55430bb2f648ad14bc76646b5a5c70daef56a5","claim":"Fulcrum Therapeutics, Inc. reported the third quarter of 2022 results: revenue $1.2 million, net income Net loss was $23.7 million.","evidence_excerpt":"Third Quarter 2022 Financial Results • Cash Position: As of September 30, 2022, cash, cash equivalents, and marketable securities were $221.8 million as compared to $218.2 million as of December 31, 2021. The increase in cash is primarily tied to our equity offering in August 2022, partially offset by our net cash used in operating activities. • Collaboration Revenue: Collaboration revenue was $1.2 million for the third quarter of 2022 as compared to $4.9 million for the third quarter of 2021. The decrease of $3.7 million was primarily due to the winding down of Fulcrum's collaboration agreement with Acceleron Pharma Inc., a wholly owned subsidiary of Merck & Co., Inc. • Operating Expenses: Total operating expenses were $25.5 million for the third quarter of 2022 as compared to $25.7 million for the third quarter of 2021. A decrease of $1.7 million in R&D expenses was primarily due to reduced discovery and external research and development costs. This was partially offset by an increas","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680581/000095017022022910/0000950170-22-022910-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Revenue","value":"$1.2 million"},{"label":"Net income","value":"Net loss was $23.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}